Fast Five Quiz: Chronic Myelogenous Leukemia Management

Emmanuel C. Besa, MD


September 21, 2022

According to 2022 NCCN Clinical Practice Guidelines, the first-generation TKI, imatinib, is a preferred first-line agent for low-risk patients in the chronic phase of CML. Other preferred agents include the second-generation TKIs bosutinib, dasatinib, or nilotinib. A clinical trial may also be considered.

Learn more about the management of CML.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.